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a b s t r a c t
Alkaptonuria is a rare genetic disorder characterized by a high
level of circulating (and urine) homogentisic acid (HGA), which
contributes to ochronosis when it is deposited in connective tissue
as a pigmented polymer. In an observational study carried out by
National AKU Centre (NAC) in Liverpool, a total of thirty-nine AKU
patients attended yearly visits in varying numbers. At each visit a
mixture of clinical, joint and spinal assessments were carried out
and the results calculated to yield an AKUSSI (Alkaptonuria
Severity Score Index), see Nitisinone arrests ochronosis and“
decreases rate of progression of Alkaptonuria: evaluation of the
effect of nitisinone in the United Kingdom National Alkaptonuria
Centre (Ranganath at el., 2018). The aim of this data article is to” 
produce visual representation of the change in the components of
AKUSSI over 3 years, through radar charts. The metabolic effect of
nitisinone is shown through box plots.
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
( ).http://creativecommons.org/licenses/by/4.0/
Speci cations tableﬁ
Subject area Rare inborn error of metabolism
More speci c subject area Tyrosine pathway disorder, Alkaptonuria, AKUSSI, severity, nitisi-ﬁ
none, homogentisic acid, natural history
Type of data Radar charts and box plots
How data was acquired Clinical assessments including subjective pain scoring, photographs,
history, ultrasound abdomen, echocardiogram, dual energy x-ray
absorptiometry,
x-ray spine and PET-CT scan
Data format Raw data
Experimental factors Observations were made over 3 years before nitisinone and over
3 years after in a cohort of patients with Alkaptonuria.
Experimental features Assessments and investigations were carried out over 5 visits to
derive numerical scores, which were then used to calculate the
Alkaptonuria Severity Score Index (AKUSSI).
Data source location National AKU Centre (NAC) in Liverpool, UK
Data accessibility Data is available in this manuscript
Related research article Ranganath LR, Khedr M, Milan AM, Davison AS, Hughes AT, Usher JL,
Taylor S, Loftus N, Daroszewska A, West E, Jones A, Briggs M, Fisher
M, McCormick M, Judd S, Vinjamuri S, Grif n R, Psarelli EE, Cox TF,ﬁ
Sireau N, Dillon JP, Devine JM, Hughes G, Harrold J, Barton GJ, Jarvis
JC, Gallagher JA. Nitisinone arrests ochronosis and decreases rate of
progression of Alkaptonuria:evaluation of the effect of nitisinone in
the United Kingdom National Alkaptonuria Centre. Molecular
Genetics and Metabolism 2018 (in press) .[1]
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Value of the data
 Actual data is shared on the components of the AKUSSI – This data will show a visualisation of how
the AKUSSI is composed.
 This is the rst time such data is being made available in relation to nitisinone therapy ﬁ – Researchers/
Scienti c community will be able to see the impact nitisinone therapy is having on AKUSSI forﬁ
patients with Alkaptonuria.
 Data is shown both before and af ter nitisinone administration – This data is provided to show the
comparison of the AKUSSI before and af ter nitisinone therapy.
1. Data
The Alkaptonuria Severity Score index (AKUSSI) was developed to allow quanti cation of diseaseﬁ
morbidity and thus allow it to be used to track changes in disease as well as potential therapies.
A large number of items were characterized by clinical assessment to derive the Clinical, Joint and
Spine AKUSSI, the sum of which is the ALL AKUSSI. The data contains each component of the AKUSSI
over 5 visits, both before and af ter nitisinone therapy.
Fig. 1. Plan of the National Alkaptonuria Service: *The VAR group V0 visit consisted of the 10 patients from the SAME group
plus seven additional patients who attended the NAC twice without receiving nitisinone. The SAME refers to ten patients
attending the research study between 20 08 and 2011. The V1, V2, V3 and V4 refer to yearly visits to the NAC. The NIT 1, NIT
2 and NIT 3 refer to change scores per patient per year after one, two and three years of nitisinone therapy. The numbers of
patients in each group, their mean age and years of follow-up are also shown in the gure.ﬁ
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Figs. 2 4 – show the metabolic effect nitisinone has on patients with Alkaptonuria, through box-
plots. While show the components of AKUSSI broken down into radar charts and the scoresFigs. 5 –12 
at each medical visit with the intervention of nitisinone.
2. Experimental design, materials and methods
Overall, thirty-nine AKU patients attended the National AKU Centre (NAC) in Liverpool ( ).Fig. 1
Varying numbers attended yearly visits leading to creation of two datasets The VAR group (variable
numbers of patients at each visit) and the SAME group (the same ten patients who attended all of the
visits) (described in more detail in accompanying main manuscript). Nitisinone 2 mg was commenced
at baseline (V1) and systematic assessments were carried out at all visits.
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Fig. 2. s-HGA concentrations in SAME and VAR groups, Pre- and Post-Nitisinone. Scores are shown as box plots with and
interquartile range. The level of signi cance of results is shown as * 0.001.ﬁ p o 
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Fig. 3. u-HGA 24 concentrations in SAME and VAR groups, Pre- and Post-Nitisinone. Scores are shown as boxplots with inter-
quartile range. The level of signi cance of results is shown as * 0.0 01.ﬁ p o 
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Fig. 4. s-TYR concentrations in SAME and VAR groups, Pre- and Post-Nitisinone. Scores are shown as boxplots with inter-
quartile range. The level of signi cance of results is shown as * 0.0 01.ﬁ p o 
Fig. 5. Radar chart showing 12 of the overall clinical AKUSSI components. The graph on the left (A) is data from the SAME
group dataset and shows the mean score per variable over 5 visits (including baseline). The right graph (B) shows the same
information but for the VAR group.
Fig. 6. Radar chart showing 4 of the overall clinical AKUSSI components. The graph on the left (A) is data from the SAME group
dataset and shows the mean score per variable over 5 visits (including baseline). The right chart (B) shows the same infor-
mation but for the VAR group.
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The VAR group at visit V0 had the 10 patients from the SAME group plus 7 additional patients, who
visited the NAC before dosing. From here forward, the SAME group consists of the same 10 patients
and the VAR group consists of the SAME group as well as an additional 29, 29, 24 and 12 patients at
visits V1, V2, V3 and V4 respectively.
Assessments (AKUSSI) were carried out at V0 (pre-baseline), V1, V2, V3 and V4. Eye and ear
ochronosis, calculi (renal and prostate), osteopenia, fracture, ruptures (muscle, ligament and tendon),
aortic valve disease and hearing impairment collectively are components of the CLINICAL AKUSSI
category. Pain and scintigraphic scan joint score of 14 large joint areas (includes hip, knee, ankle,
shoulder, hand/wrist, foot and elbow), arthroscopy and joint replacements, comprise the JOINT
category. Spinal pain score (cervical, thoracic and sacroiliac), Scintigraphic scan spine score (pubic
Fig. 7. Radar chart showing the 14 large joint areas that make up the joint pain AKUSSI score. The graph on the left (A) is data
from the SAME group dataset and shows the mean score per variable over 5 visits (including baseline). The right
chart (B) shows the same information but for the VAR group.
Fig. 8. Radar chart showing the 14 large joint areas that make up the Scintigraphic scan joint AKUSSI score. The graph on the
left (A) is data from the SAME group dataset and shows the mean score per variable over 5 visits (including baseline). The right
chart (B) shows the same information but for the VAR group.
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symphysis, costochondral, lumbar, thoracic, cervical and sacroiliac), kyphosis and scoliosis comprise
the SPINE category. The overall AKUSSI score is calculated over the CLINICAL, JOINT and SPINE scores.
In order to produce a visualisation of the AKUSSI assessment results and illustrate the effect
nitisinone has over time, radar charts were produced. A radar chart is a graphical method used for
displaying multivariate data, represented on axes starting from the same point. Each spoke on the
chart represents one variable and the 5 different plots on each spoke, represent the mean of the data
at each of the 5 visits (V0, V1, V2, V3, and V4). HGA was measured on acidi ed 24 h urine (u-HGAﬁ 24)
and acidi ed serum (s-HGA) samples from each visit as previously described by tandem massﬁ
spectrometry.
The metabolic effect has been captured visually through bar charts and statistically analyzed by
Student's t test (paired for the SAME group and unpaired for the VAR group).‘ ’ 
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Fig. 9. Radar chart showing the 4 components of the overall joint AKUSSI score. The graph on the left (A) is data from the SAME
group dataset and shows the mean score per variable over 5 visits (including baseline). The right chart (B) shows the same
information but for the VAR group.
Fig. 10. Radar chart showing the 4 components of the spinal AKUSSI pain score and the 6 components of the Scintigraphic scan
AKUSSI pain score. The graph on the left (A) is data from the SAME group dataset and shows the mean score per variable over
5 visits (including baseline). The right chart (B) shows the same information but for the VAR group.
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3. Nitisinone effect on metabolic measurements
The effect of nitisinone on serum and 24 h urine HGA both in SAME and VAR groups, as well as
serum tyrosine in SAME and VAR groups is shown in .Figs. 2–4
4. Visualisation of AKUSSI components over time
The radar charts displayed below show different components of the AKUSSI assessment. In each
ﬁgure the same components are shown for the SAME group (left chart, A) and also for the VAR group
(right chart, B). As the VAR group consists of a mixture of participants, it is included for validation
purposes. Each radar chart displays the upper range score around the outside of the graph, while each
web line represents a percentage of the total score.
An improvement in mean score between the later visit times for the scintigraphic ankle and knee
scan score is seen in (lef t chart). This can also be seen in (right chart).Fig. 8 Fig. 8 
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Fig. 11. Radar chart showing the 4 components of the overall spine AKUSSI score. The graph on the left (A) is data from the
SAME group dataset and shows the mean score per variable over 5 visits (including baseline). The right chart (B) shows the
same information but for the VAR group.
Fig. 12. Radar chart showing the 3 overall components of the AKUSSI score. The graph on the lef t (A) is data from the SAME
group dataset and shows the mean score per variable over 5 visits (including baseline). The right chart (B) shows the same
information but for the VAR group.
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